AbbVie
ABBV
$172.99
Share price
0.76%
Change (1 day)
5.32%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Revenue for AbbVie (ABBV)
Revenue in 2024 (TTM): $56.33 Billion USD
According to AbbVie's latest financial reports the company's current revenue (TTM 
) is $56.33 Billion USD. an increase over the revenue in the year 2023 that were of $54.31 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AbbVie from 2011 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | $56.33 B | 3.71% |
| 2023 | $54.31 B | -6.44% |
| 2022 | $58.05 B | 3.3% |
| 2021 | $56.19 B | 22.69% |
| 2020 | $45.80 B | 37.69% |
| 2019 | $33.26 B | 1.57% |
| 2018 | $32.75 B | 16.08% |
| 2017 | $28.21 B | 10.06% |
| 2016 | $25.63 B | 12.16% |
| 2015 | $22.85 B | 14.52% |
| 2014 | $19.96 B | 6.23% |
| 2013 | $18.79 B | 2.23% |
| 2012 | $18.37 B | 5.36% |
| 2011 | $17.44 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | $63.62 B | 12.94% | 🇺🇸 USA |
 | $48.30 B | -14.26% | 🇺🇸 USA |
 | $45.04 B | -20.04% | 🇺🇸 USA |
 | $33.42 B | -40.67% | 🇺🇸 USA |
 | $28.75 B | -48.96% | 🇺🇸 USA |
 | $9.67 B | -82.82% | 🇺🇸 USA |
 | $40.18 B | -28.67% | 🇬🇧 UK |
 | $54.07 B | -4.01% | 🇬🇧 UK |
 | $2.35 B | -95.82% | 🇺🇸 USA |